# Endocrinology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: modern shifted

- To: Marcus Delgado, MD, Endocrinology
- Urgency: Routine, within four weeks

## Referral question

Low bone mass on DXA with a FRAX risk above the treatment thresholds in a 63-year-old woman after a fall with a hand fracture. Please confirm how to classify her, whether to treat and with what, and how to monitor. **S**

## Questions for the consultant

1. Is this osteoporosis or low bone mass, and should the hand fracture count as a fragility fracture in FRAX and in the diagnosis?
2. Is drug treatment indicated, and what is her risk category?
3. Which drug do you recommend for her, and what has to be in place before the first dose?
4. Is the secondary-causes work-up adequate?
5. How should we monitor her, when should DXA be repeated, and how long should treatment last before a drug holiday is considered?
6. Do her falls, her past smoking, or her alcohol use disorder in remission change the plan?

## Pertinent history

Postmenopausal since her early fifties, no hormone therapy, no glucocorticoids. Fell from standing height last year and broke her hand; one account also describes a second fall with an ankle fracture. She was told after an earlier test that she had early bone loss; no report is available. Her mother had osteoporosis with arm and hip fractures. Former heavy smoker, quit more than fifteen years ago; alcohol use disorder in sustained remission for more than fifteen years. Height 164.0 cm, about 2 cm below her recalled tallest; BMI 24.5. DXA today: lumbar spine T-score -2.3, femoral neck -2.0, total hip -1.7. Lateral spine DXA: no vertebral fracture. FRAX with femoral neck BMD (previous fracture and parental hip fracture entered): 22 percent major osteoporotic, 3.6 percent hip. Calcium 9.4, albumin 4.2, phosphate, magnesium, alkaline phosphatase, PTH 54, creatinine 0.8 (eGFR 81), TSH, and hemoglobin normal; 25-hydroxyvitamin D 24 ng/mL; fasting CTX 560 pg/mL; 24-hour urine calcium ordered. Calcium intake about 800 mg a day. Timed Up and Go 11 seconds, tandem stance 8 seconds. Started vitamin D3 2000 units daily today. **S**

- Ann Richards was born Dorothy Ann Willis on September 1, 1933, in Lakeview, near Waco, Texas. **D**
- She was elected Texas state treasurer in 1982, gave the keynote address at the 1988 Democratic National Convention, was elected governor of Texas in 1990, and served one term after losing her bid for re-election in 1994. **D**
- She spoke openly about her past heavy drinking ("I smoked like a chimney and drank like a fish"), entered treatment, and emerged sober; one biography dates the treatment to 1980 and describes it as successful. **D**
- She said publicly that her mother had osteoporosis, broke "her arm, her hip," and developed a hump, and that osteoporosis was not the cause of her mother's death but led to it. **D**
- Because of her mother's fractures, she asked her doctor at an annual checkup to test her bone density. **D**
- She had a bone density test after falling and breaking her hand. CBS News (2003) and a publisher's summary date this to 1996, and CBS says she fell twice and broke her hand and her ankle; a Publishers Weekly review dates the hand fracture to 1994. **D**
- The bone density test showed osteopenia, which CBS News and the publisher's summary call an early stage of osteoporosis; in other interviews she said she had osteoporosis or early osteoporosis. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Lumbar spine (L1-L4) T-score: -2.3 (low); Femoral neck T-score: -2 (low); Total hip T-score: -1.7 (low); FRAX 10-year major osteoporotic fracture risk: 22%; FRAX 10-year hip fracture risk: 3.6%; Calcium: 9.4 mg/dL; Albumin: 4.2 g/dL; Creatinine: 0.8 mg/dL; eGFR: 81 mL/min/1.73 m²; Phosphate: 3.5 mg/dL; Magnesium: 2 mg/dL; Alkaline phosphatase: 84 U/L; PTH: 54 pg/mL; TSH: 1.9 mIU/L; Hemoglobin: 13.3 g/dL; ALT: 21 U/L; 25-hydroxyvitamin D: 24 ng/mL (low); Serum CTX (fasting morning sample): 560 pg/mL; PHQ-9: 2; AUDIT-C: 0. All results are synthetic.

BP 124/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 66 kg; BMI 24.5 kg/m². All vital signs are synthetic.

## Current medications

- Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily **S**

## Plan so far

- Calcium about 1200 mg a day in total, from food first, and vitamin D3 2000 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcohol. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020) **S**
- Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision check. Guideline: The clinician's guide to prevention and treatment of osteoporosis (2022); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026) **S**
- Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scanner. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); Osteoporosis to Prevent Fractures: Screening (2025) **S**
- Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visit. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
